Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced non-squamous non-small cell lung cancer - EAGLES

Trial Profile

Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced non-squamous non-small cell lung cancer - EAGLES

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EAGLES
  • Sponsors Roche
  • Most Recent Events

    • 14 Jul 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 23 Jun 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as per ClinicalTrials.gov record.
    • 23 Jun 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Jun 2014 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top